A5033242759- Sarcoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Vascular Tumors and Angiosarcomas
- Hedgehog Signaling Pathway Studies
- Full-Duplex Wireless Communications
- Cutaneous Melanoma Detection and Management
- Nonmelanoma Skin Cancer Studies
- Cancer and Skin Lesions
- Antenna Design and Analysis
- Plant Virus Research Studies
- Brain Metastases and Treatment
- Bone Tumor Diagnosis and Treatments
- Bacteriophages and microbial interactions
- Cancer-related Molecular Pathways
- Gastrointestinal Tumor Research and Treatment
- Autoimmune Bullous Skin Diseases
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Computational Drug Discovery Methods
- Ocular Oncology and Treatments
- Gastrointestinal disorders and treatments
- Cancer Diagnosis and Treatment
The Maria Sklodowska-Curie National Research Institute of Oncology
2018-2025
Incyte (United States)
2023
National Institute of Oncology
2022-2023
Oxfam
2022
John Wiley & Sons (United States)
2022
John Wiley & Sons (United Kingdom)
2022
Narodowy Instytut Leków
2021
Wojskowy Instytut Medyczny
2021
Centralny Szpital Kliniczny
2021
Medical University of Lublin
2001
Clear cell sarcoma (CCS), formerly called soft tissue melanoma, is a rare malignant (STS) characterized by propensity for lymphatic spread and poor prognosis. can be distinguished t(12; 22) (q13; q12) translocation, which in addition to diagnostic implications may important targeted treatment the future. occurs mainly on extremities, most often shin (in feet ankle area), tendons, aponeurosis, at young age. Considering significant ability develop metastases regional lymph nodes (about 30% of...
Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT this tumor are scarce. This study aimed investigate utilization osteosarcomas in recent 20 years identify factors related patients' response radiation.We performed a retrospective analysis patients irradiated treatment. We planned assess differences between periods 2000-2010 2011-2020, risk associated with local progression (LP), determine whether RT-related parameters LP, calculate survival.A total...
2599 Background: In cancer treatment (tx), loss of T-cell function is associated with progressive expression checkpoint (CP) molecules, and resistance or relapse following PD-(L)1 inhibitor therapy a high unmet need. LAG-3 TIM-3 are key CP pathways implicated in to PD-1 inhibitors have shown synergistic effects upon triple inhibition murine model. This open-label, nonrandomized phase 1/2 study (NCT04370704) aims determine optimal doses preliminary safety efficacy for the monoclonal antibody...
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point progression-free survival.Patients variety STS subtypes were randomised 1:1 (200 mg b.i.d. p.o. until disease progression) or (3 g/m2 i.v. days 1-3, every 21 for ≤6 cycles). A Korn design applied aiming detect an improvement median...
Pembrolizumab and nivolumab (anty-PD-1 antibody) are commonly used for the treatment of melanoma patients. However, their efficacy safety have never been directly compared, leaving little guidance clinicians to select best therapy. The study included patients with inoperable or metastatic treated in first line anti-PD-1 immunotherapy (nivolumab pembrolizumab). In total 1037 were enrolled study, 455 (44%) pembrolizumab 582 (56%) nivolumab. estimated median overall survival (OS) groups was...
Abstract Incidence rates of Merkel cell carcinoma (MCC), an uncommon skin cancer with aggressive disease course, have increased in recent decades. Limited treatment options are available for patients metastatic MCC (mMCC). Avelumab, anti‐programmed death‐ligand 1 monoclonal antibody, became the first approved mMCC after results phase 2 JAVELIN 200 study. Prior to its regulatory approval, expanded access program (EAP) enabled compassionate use avelumab mMCC. Here we report findings from...
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with high risk of recurrence and poor prognosis. The treatment locally advanced disease involves surgery radiotherapy. To analyze real-life patterns clinical outcomes, we conducted retrospective analysis data from 161 MCC patients treated curative intent in four oncological centers Poland. median age at diagnosis was 72 years (30–94); 49.7% were male. Lymph node (LN) involvement found 26.9% patients. Sentinel lymph biopsy (SLNB)...
Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer. The basis of treatment surgical resection. locally advanced and metastatic disease currently based on sonidegb or vismodegib, small molecule inhibitors hedgehog signalling pathway.The study aimed to retrospectively analyse efficacy safety with vismodegib in 108 patients treated from August 1st, 2017 December 31st, 2020. primary objective was evaluate response rate (ORR), overall survival (OS) progression-free rates....
Histopathological evaluation of lymph nodes in Merkel cell carcinoma has become crucial progression estimation and treatment modification. This study was undertaken to determine the most sensitive immunohistochemical panel for detecting MCC nodal metastases. We included 56 patients with 102 metastatic nodes, which were tested seven antibodies: cytokeratin (CKAE1/AE3), CK20, chromogranin A, synaptophysin, INSM1, SATB2, neurofilament (NF). Tissue microarrays (TMA) composed 2-mm tissue cores...
The basic principle for the diagnosis of melanoma metastases in brain should be management multidisciplinary teams including at least a neurosurgeon, radiotherapist and clinical oncologist experienced treatment CNS. Detection lesions is associated with poor prognosis; are cause death 20–50% patients, symptomatic tumours direct about 90% patients. Treatment CNS may include local and/or systemic treatment. In last 5 years, 10 new advanced drugs have been registered Europe. Two-drug therapy...
Merkel cell carcinoma (MCC) is a rarely occurring skin cancer of high malignancy. It develops, most probably, from the neuroendocrine cells (Merkel's cells). The frequent location this head and neck (44–48% cases), then in upper limbs (about 19% cases) lower (16–20% cases). aetiology unknown, yet some role its pathogenesis played by ultraviolet light immunosuppression. basis therapy cases with locoregional spread surgical intervention, whilst more advanced cases, an effective systemic...